Table of Contents
- Trial overview
- Nutrition after oesophagectomy
- Early versus postponed supplementary parenteral nutrition
- What the trials measure
- Who may take part
- Why Phase 3 matters
Trial overview
The source data does not list a trial directly studying Zinc Sulphate Heptahydrate. Instead, it lists two authorised interventional studies about nutrition support after major surgery.[1][1]
Both studies are Phase 3 trials, which means they are testing treatments in larger groups of patients and comparing outcomes in real clinical settings.[1][1]
Nutrition after oesophagectomy
One trial is titled Route of nutrition and muscle wasting after oesophagectomy.[1] It is a Phase 3 interventional study with 38 planned participants and an authorised status.[1]
This study aims to understand how the route of nutrition affects cachexia, which means severe weight and muscle loss, after oesophagectomy.[1]
The intervention listed is SmofKabiven emulsion for infusion, which is given by parenteral use, meaning through a vein rather than by mouth.[1]
Early versus postponed supplementary parenteral nutrition
The second trial is titled Early versus postponed supplementary parenteral nutrition after major emergency abdominal surgery.[1] It is also a Phase 3 interventional study and is authorised, with 342 planned participants.[1]
This study compares early and postponed supplementary parenteral nutrition after major emergency abdominal surgery.[1] The goal is to see whether one approach lowers the risk of nosocomial infections, which are infections that happen during a hospital stay.[1]
The interventions listed are SmofKabiven Perifer and SmofKabiven, both given by infusion.[1]
What the trials measure
The main outcome in the oesophagectomy study is the mean difference in muscle size on CT scan from before surgery to 10 days after surgery.[1]
This outcome helps researchers see whether nutrition route is linked to less muscle loss after surgery.[1]
The main outcome in the emergency abdominal surgery study is a reduction in the rate of infectious complications during admission.[1]
This outcome focuses on whether the timing of supplementary parenteral nutrition affects infection risk while the patient is in hospital.[1]
Who may take part
The source data shows that the target populations are adults after oesophagectomy and adults after major emergency abdominal surgery.[1][1]
No additional eligibility details are provided in the source data, such as age limits, lab tests, or medical exclusions.[1][1]
Why Phase 3 matters
Phase 3 studies are usually used to compare treatment approaches in larger groups and measure important health outcomes.[1][1]
In these two trials, the researchers are not only looking at whether nutrition support can help, but also at specific recovery results such as muscle size and infection rates.[1][1]
